Lach De Hayr
banner
lachdehayr.bsky.social
Lach De Hayr
@lachdehayr.bsky.social
Post-doc at Khromykh lab. Virology and non-coding RNA. Queensland, Australia.
@slonchak.bsky.social presenting his work on viral pathogenesis in human brain organoid models using single cell sequencing. Hisnlast presentation at #uqscmb before he heads to @qimrb.bsky.social to head his own lab
May 14, 2025 at 2:11 AM
Reposted by Lach De Hayr
Host tRNAs as novel player in antiviral response. Presented by @lachdehayr.bsky.social at Lorne I&I conference @theviin.bsky.social
February 20, 2025 at 6:26 AM
Reposted by Lach De Hayr
First science bite of session 9 we have @lachdehayr.bsky.social from UQ! Teaching us all about his awesome work on Flavivirus infections and tRNA 🦠 #lorneiandi
February 20, 2025 at 6:20 AM
@slonchak.bsky.social's excellent presentation on his work studying WNV neuropathology using state of the art human brain organoids and single cell sequencing #UQSCMB
Exciting work by Dr Andrii Slonchak on using virus-inclusive scRNA-Seq to reveal the mechanism of flavivirus neuropathogenesis #lorneiandi
February 20, 2025 at 1:17 AM
@connorapscott.bsky.social from UQ discussing his work on JEV epitopes for therapeutic design at Lorne I&I @theviin.bsky.social
#UQSCMB
February 19, 2025 at 6:28 AM
Just recently published some work from a previous role looking at mutations causing intellectual disability. Proud this work can contribute to better outcomes for children.
Biallelic variants in GTF3C3 result in an autosomal recessive disorder with intellectual disability
This study details a novel syndromic form of autosomal recessive intellectual disability resulting from recessive variants in GTF3C3, encoding a key component of the DNA-binding transcription factor IIIC, which has a conserved role in RNA polymerase III-mediated transcription.
www.gimjournal.org
December 8, 2024 at 11:39 AM
Reposted by Lach De Hayr
First isolation of a chu-like virus (TDCV)....from primary facial (transmissible) tumor cells of the Tasmanian devil. Most closely related to a virus from a sea squirt 🤷‍♂️ Work led by @julienmelade.bsky.social with @erinharvey.bsky.social and Andy Flies et al. www.biorxiv.org/content/10.1...
Isolation of an infectious mammalian chu-like virus from tumor cells of the endangered Tasmanian devil (Sarcophilus harrisii)
Jingchuvirales (negative-sense RNA viruses) were initially discovered in invertebrates, with both exogenous and endogenous jingchuviruses subsequently identified in fish, reptiles and mammals. To date...
www.biorxiv.org
November 26, 2024 at 6:11 AM
Reposted by Lach De Hayr
New from the RNA Virology lab: We characterized 2021-2022 vaccine & hybrid immunity cohorts for #SARSCoV2 in QLD AUS and generated an ΔORF3-8 attenuated strain. We validated this virus in neutralization assays with a sera panel and hope for future use in BSL2/PC2.
www.biorxiv.org/content/10.1...
November 13, 2024 at 12:35 AM
Our paper and the first from our PhD student talking about the current state of flavivirus vaccines. Are our current strategies failing, and are their other options? Maybe new targets are needed. Read it below.
The Flavivirus Non-Structural Protein 5 (NS5): Structure, Functions, and Targeting for Development of Vaccines and Therapeutics
Flaviviruses, including dengue (DENV), Zika (ZIKV), West Nile (WNV), Japanese encephalitis (JEV), yellow fever (YFV), and tick-borne encephalitis (TBEV) viruses, pose a significant global emerging threat. With their potential to cause widespread outbreaks and severe health complications, the development of effective vaccines and antiviral therapeutics is imperative. The flaviviral non-structural protein 5 (NS5) is a highly conserved and multifunctional protein that is crucial for viral replication, and the NS5 protein of many flaviviruses has been shown to be a potent inhibitor of interferon (IFN) signalling. In this review, we discuss the functions of NS5, diverse NS5-mediated strategies adopted by flaviviruses to evade the host antiviral response, and how NS5 can be a target for the development of vaccines and antiviral therapeutics.
www.mdpi.com
October 29, 2024 at 11:41 AM